Navigation Links
GAD/IA-2 Autoantibody Screen

ProductsGAD/IA-2 Autoantibody Screen
Company KRONUS
Item GAD/IA-2 Autoantibody Screen
Features 
Description The autoimmune destruction of the insulin-producing pancreatic beta cells generally occurs over a period of time leading to the eventual onset of overt diabetes mellitus. During this extended pre-clinical phase, the characteristic circulation of autoantibodies against a variety of islet cell antigens including glutamic acid decarboxylase (GAD65), IA-2 (a tyrosine phosphatase-like protein), and insulin provides early markers of autoimmune disease activity.

Measurement of these immunologic markers has been shown to be of considerable value in assisting the attending clinician with the diagnosis and management of patients with diabetes and in predicting the development of diabetes in first-degree relatives of diabetic patients.

Info KRONUS
Customer Service: (800) 457-6687
Web site: http://www.kronus.com

Related medicine products :

1. Thyroglobulin Autoantibody - ELISA
2. Thyroglobulin Autoantibody - RIA
3. Thyroid Peroxidase (TPO) Autoantibody - RIA
4. TSH Receptor (TSHR) Autoantibody Coated-Tube (CT)
5. Thyroid Peroxidase (TPO) Autoantibody - ELISA
6. TSH Receptor (TSHR) Autoantibody - ELISA
7. TSH Receptor (TSHR) Autoantibody - RIA
8. Insulin Autoantibody (IAA)
9. Glutamic Acid Decarboxylase (GAD65) Autoantibody RIA
10. IA-2 Autoantibody ELISA
11. Glutamic Acid Decarboxylase (GAD65) Autoantibody ELISA
... instrument introduction. The design of the ... eliminates transition profile between the introducer ... through fascial tissue and strictured areas. ... introducer sheath and introducer dilator during ...
... Used for temporary ... ureteropelvic junction to the ... peel-open packages. Intended for ... evaluation is advised; C-Flex® ...
Used for antegrade placement of a safety wire guide prior to endourological procedures. Supplied sterile in peel-open packages. Intended for one-time use....
Used to gain percutaneous access into the renal pelvis to treat stone disease. The dual lumen catheter and the Peel-Away® introducer are sized for use in pediatric patients. Supplied sterile in p...
Medicine Products:
(Date:10/13/2017)... ... October 13, 2017 , ... ProVest Insurance Group, ... Dallas, Miami, and Raleigh regions, is organizing an extended charity drive to benefit ... deadly chromosome abnormality. , After struggling since birth with several health challenges, T.J. ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... process to promote standards of excellence for the field of eating disorders, announces ... 22 – 25, 2018 in Orlando, Florida at the Omni Resort at ChampionsGate. ...
(Date:10/13/2017)... ... 13, 2017 , ... Many families have long-term insurance that covers care for ... a waiver for care if the client has a cognitive impairment diagnosis. , ... care, is often waived, so the benefits from their insurance start immediately,” said Mechell ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... be giving viewers the lowdown on sciatica in a new episode of "Success ... focuses on current events and innovation and investigates each subject in-depth with passion ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
(Date:9/28/2017)... Cohen Veterans Bioscience and Early Signal Foundation announce a ... sensors for real-time monitoring of patients with trauma-related and ... focused on disruptive health solutions for rare disorders and ... record and integrate behavioral, cognitive, physiological and contextual data. ... ...
(Date:9/23/2017)... HORSHAM, Pa. , Sept. 22, 2017 ... received a complete response letter from the U.S. Food ... (BLA) seeking approval of sirukumab for the treatment of ... response letter indicates additional clinical data are needed to ... of moderately to severely active RA. ...
Breaking Medicine Technology: